Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery disease
- 1 October 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Blood Coagulation & Fibrinolysis
- Vol. 21 (7), 674-678
- https://doi.org/10.1097/mbc.0b013e32833e47c1
Abstract
Platelet glycoprotein IIb/IIIa is a membrane receptor which plays a key role in coronary artery disease and thrombotic events. However, there is a considerable controversy regarding the clinical impact of glycoprotein IIIa platelet antigen 1 (PlA1)/platelet antigen 2 (PlA2) polymorphism as a risk factor for myocardial infarction. To evaluate the association between glycoprotein IIIa PlA1/PlA2 polymorphism and 1-year cardiovascular events occurrence in aspirin-treated patients with stable coronary artery disease. We prospectively included 188 postacute coronary syndrome patients (183 men) aged 59 ± 10 years and receiving aspirin (250 mg/day). The clinical outcome at 1 year was the composite end point of nonfatal myocardial infarction, stroke, recurrent unstable angina or cardiac death. Genotyping for PlA1/PlA2 polymorphism was conducted using PCR and restriction fragment length polymorphism analysis. The genotype distribution of glycoprotein IIIa PlA1/PlA2 polymorphism was PlA1/PlA1, 55.3%; PlA1/PlA2, 39.3% and PlA2/PlA2, 4%. Incidence of composite end point in homozygous PlA1/PlA1 carriers was significantly higher than in PlA2/PlA2 and PlA1/PlA2 patients [14.4 vs. 3.6% odds ratio 4.5 (1.2–16.6, 95% confidence interval); P = 0.012]. Multivariate analysis identified three strong predictive factors of cardiac death: age more than 65 years [odds ratio = 6.8, (1.4–34, 95% confidence interval); P = 0.018], ventricular ejection fraction less than 50% [odds ratio = 8.6, (1.7–42.6, 95% confidence interval); P = 0.008] and homozygous PlA1/PlA1 genotype [odds ratio = 8.8, (1.0–78.6, 95% confidence interval); P = 0.014]. Our results demonstrated that glycoprotein IIIa PlA1/PlA1 genotype carriers have a significantly increased risks of acute vascular ischemic events associated with a poor prognosis at 1 year. These postacute coronary syndrome patients might require an optimized secondary antithrombotic prophylaxis strategy.Keywords
This publication has 31 references indexed in Scilit:
- Role of PLA2 polymorphism on clinical events after percutaneous coronary interventionAcute Cardiac Care, 2009
- Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stentingThrombosis Journal, 2007
- The genetics of aspirin resistanceInternational Journal of Clinical Practice, 2007
- Effect of glycoprotein IIIa PlA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smokingThe American Journal of Cardiology, 2004
- Platelet glycoprotein IIb/IIIa PlA2/PlA2homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: The Copenhagen City Heart StudyJournal of the American College of Cardiology, 2003
- A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart diseaseStatistics in Medicine, 2003
- The GPIIIa (β3 integrin) PlA polymorphism in the early development of coronary atherosclerosisAtherosclerosis, 2001
- Increased Platelet Aggregability Associated With Platelet
GPIIIa Pl
A2 Polymorphism Arteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Pla1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplastyThe American Journal of Cardiology, 1998
- Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphismBritish Journal of Haematology, 1997